Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

NCT07680569 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

GC/GEJC

Interventions

BIOLOGICAL: Zolbetuximab
DRUG: Oxaliplatin + 5-Fluorouracil/Leucovorin
DRUG: CAPOX (oxaliplatin/capecitabine)

Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Collaborators

[object Object]
[object Object]
[object Object]